[go: up one dir, main page]

NO20081727L - Behandling av autoimmune sykdommer - Google Patents

Behandling av autoimmune sykdommer

Info

Publication number
NO20081727L
NO20081727L NO20081727A NO20081727A NO20081727L NO 20081727 L NO20081727 L NO 20081727L NO 20081727 A NO20081727 A NO 20081727A NO 20081727 A NO20081727 A NO 20081727A NO 20081727 L NO20081727 L NO 20081727L
Authority
NO
Norway
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
methods
Prior art date
Application number
NO20081727A
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Sven Weiler
Barbara Nuesslein-Hildesheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20081727L publication Critical patent/NO20081727L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Fremgangsmåte for å behandle ulike autoimmune sykdommer, slik som multippel sklerose, perifer neuritt, optisk neuritt, amyotrofisk lateral sklerose og uveitt ved anvendelse av spesifikke aminoalkoholderivater er frembrakt.
NO20081727A 2005-09-09 2008-04-07 Behandling av autoimmune sykdommer NO20081727L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09
PCT/EP2006/066150 WO2007028821A2 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
NO20081727L true NO20081727L (no) 2008-06-06

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081727A NO20081727L (no) 2005-09-09 2008-04-07 Behandling av autoimmune sykdommer

Country Status (28)

Country Link
US (1) US20080200438A1 (no)
EP (2) EP2295049B1 (no)
JP (4) JP5244598B2 (no)
KR (3) KR20140117704A (no)
CN (1) CN101257899B (no)
AT (1) ATE489948T1 (no)
AU (2) AU2006289100B2 (no)
BR (1) BRPI0615906A2 (no)
CA (2) CA2820510A1 (no)
CY (1) CY1111285T1 (no)
DE (1) DE602006018629D1 (no)
DK (2) DK2295049T3 (no)
ES (2) ES2357426T3 (no)
IL (2) IL189665A (no)
JO (1) JO2655B1 (no)
MA (1) MA29787B1 (no)
MX (1) MX2008003170A (no)
NO (1) NO20081727L (no)
NZ (2) NZ566137A (no)
PL (2) PL2295049T3 (no)
PT (2) PT1926483E (no)
RU (2) RU2424795C2 (no)
SG (1) SG165364A1 (no)
SI (2) SI1926483T1 (no)
TN (1) TNSN08103A1 (no)
TW (2) TWI372620B (no)
WO (1) WO2007028821A2 (no)
ZA (1) ZA200801694B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
PT2511262T (pt) 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
BRPI0617077A2 (pt) * 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ574011A (en) * 2006-08-08 2011-10-28 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
CA2659599C (en) * 2006-08-08 2014-06-17 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
JP5198293B2 (ja) * 2007-02-13 2013-05-15 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
CN102123735A (zh) * 2008-05-20 2011-07-13 杏林制药株式会社 诱导缓解维持剂
EP2328571B1 (en) * 2008-08-18 2014-06-18 Novartis AG Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
AU2011249789B2 (en) * 2010-05-06 2015-03-19 Novartis Ag Dosage regimen of diaryl sulfide derivatives
KR20130066630A (ko) * 2010-05-06 2013-06-20 노파르티스 아게 자가면역 질환의 치료

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
CN1178653C (zh) * 1997-02-27 2004-12-08 三菱制药株式会社 药物组合物
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
US7482491B2 (en) * 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
CN1708293A (zh) * 2002-09-24 2005-12-14 诺瓦提斯公司 治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂
CA2499977A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Edible solid composition and dosage form
WO2004074297A1 (ja) * 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
NZ592339A (en) * 2003-04-08 2012-09-28 Novartis Ag Solid pharmaceutical compositions of S1P receptor agonist with sugar alcohol
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
MXPA06002349A (es) * 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
US20090275553A1 (en) * 2004-11-29 2009-11-05 Kovarik John M Dosage regimen of an s1p receptor agonist
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2015025002A (ja) 2015-02-05
CN101257899A (zh) 2008-09-03
JP2017019854A (ja) 2017-01-26
CY1111285T1 (el) 2015-08-05
JO2655B1 (en) 2012-06-17
RU2011111117A (ru) 2012-09-27
NZ588372A (en) 2012-03-30
MX2008003170A (es) 2008-03-18
JP6077265B2 (ja) 2017-02-08
WO2007028821A2 (en) 2007-03-15
DE602006018629D1 (de) 2011-01-13
AU2006289100B2 (en) 2010-07-22
SG165364A1 (en) 2010-10-28
JP2009507810A (ja) 2009-02-26
ZA200801694B (en) 2009-09-30
IL189665A0 (en) 2008-06-05
IL233328A0 (en) 2014-08-31
ES2529724T3 (es) 2015-02-25
JP5244598B2 (ja) 2013-07-24
JP2013010802A (ja) 2013-01-17
BRPI0615906A2 (pt) 2011-05-31
KR20140117704A (ko) 2014-10-07
EP1926483A2 (en) 2008-06-04
EP2295049B1 (en) 2014-11-26
PL1926483T3 (pl) 2011-05-31
SI2295049T1 (sl) 2015-03-31
MA29787B1 (fr) 2008-09-01
RU2493840C2 (ru) 2013-09-27
HK1149906A1 (en) 2011-10-21
US20080200438A1 (en) 2008-08-21
DK1926483T3 (da) 2011-03-14
PT1926483E (pt) 2011-03-03
KR20140019033A (ko) 2014-02-13
EP2295049A1 (en) 2011-03-16
KR101476591B1 (ko) 2014-12-24
WO2007028821A3 (en) 2007-05-03
AU2010224355A1 (en) 2010-10-14
NZ566137A (en) 2011-05-27
ATE489948T1 (de) 2010-12-15
KR20080046231A (ko) 2008-05-26
RU2008113187A (ru) 2009-10-20
RU2424795C2 (ru) 2011-07-27
CA2620554C (en) 2013-12-17
ES2357426T3 (es) 2011-04-26
TWI372620B (en) 2012-09-21
TW201034659A (en) 2010-10-01
PL2295049T3 (pl) 2015-04-30
AU2010224355B2 (en) 2012-03-29
PT2295049E (pt) 2015-03-02
CN101257899B (zh) 2012-10-03
EP1926483B1 (en) 2010-12-01
AU2006289100A1 (en) 2007-03-15
SI1926483T1 (sl) 2011-04-29
TNSN08103A1 (en) 2009-07-14
CA2820510A1 (en) 2007-03-15
KR101476451B1 (ko) 2014-12-24
CA2620554A1 (en) 2007-03-15
TWI376223B (en) 2012-11-11
DK2295049T3 (en) 2015-02-23
IL189665A (en) 2014-07-31
TW200803829A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
NO20081727L (no) Behandling av autoimmune sykdommer
NO20054407L (no) Cannabinoid reseptor ligander og deres anvendelser
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
NO20076401L (no) Diarylhydantoinforbindelser
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
NO20076412L (no) Heterosykliske inhibitorer av mek og fremgangsmater for anvendelse derav
NO20080318L (no) Anvendelse av enkelt dose av CD-20-spesifikke bindingsmolekyler
TW200509892A (en) Novel aminobenzophenone compounds
NO20075706L (no) Pyrrolopyridinbaserte inhibitorer av dipeptidylpeptidase IV og metoder
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
MX2025003515A (es) Moduladores de akt1
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
WO2006034391A3 (en) Indole inhibitors of 15-lipoxygenase
MX2007013306A (es) Nuevas tiazolidinonas sin nitrogeno basico, su produccion y su uso como agentes farmaceuticos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application